|
Enasidenib Clinical Trials
10 actively recruiting trials across 8 locations
Also known as: AG 221, AG-221, AG221, CC-90007, CC-90007 Free Base, Idhifa
Houston, Texas2 trials
Other1 trial
Birmingham, Alabama1 trial
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
University of Alabama at Birmingham Cancer Center
Phase 2
Tucson, Arizona1 trial
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Banner University Medical Center - Tucson
Phase 2
Baltimore, Maryland1 trial
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Johns Hopkins University/Sidney Kimmel Cancer Center
Phase 2
Bethesda, Maryland1 trial
Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
National Institutes of Health Clinical Center
Phase 2
Boston, Massachusetts1 trial
A Study of Enasidenib in People With T-Cell Lymphoma
Dana Farber Cancer Institute (Data Collection Only)
Phase 2
Basking Ridge, New Jersey1 trial
A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)
Memorial Sloan Kettering Basking Ridge
Phase 1
Columbus, Ohio1 trial
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Ohio State University Comprehensive Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.